ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,067.00
-1.24%
S&P ASX All Technology
3,766.30
-0.74%
Brent Oil
72.72
0.00%
US Dollar vs AUD
1.59949
0.00%
Bitcoin
95,292.28
-1.97%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Adicet Bio Inc (ACET)

  7. Adicet Bio Inc (ACET) News

Adicet Bio Inc

Adicet Bio Inc (ACET)

NASDAQ
0.91
0.0497
(5.78%)
Closed 23 December 8:00AM
Delayed by 15 minutes
0.95
0.04
(4.40%)
After Hours: 10:19AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

ACET News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
20 December 2024
ACET (5.78%)

Form 8-K - Current report
Edgar (US Regulatory)
28 November 2024
ACET (5.78%)

Form 8-K - Current report
Edgar (US Regulatory)
19 November 2024
ACET (5.78%)

Form 8-K - Current report
Edgar (US Regulatory)
16 November 2024
ACET (5.78%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
15 November 2024
ACET (5.78%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
14 November 2024
ACET (5.78%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 November 2024
ACET (5.78%)

Form 8-K - Current report
Edgar (US Regulatory)
07 November 2024
ACET (5.78%)

ACET Discussion

View Posts
Monksdream Monksdream 4 months ago
ACET under $2
👍️0
Monksdream Monksdream 5 months ago
ACET under $2
👍️0
Monksdream Monksdream 6 months ago
ACET under $2
👍️0
Monksdream Monksdream 6 months ago
ACET new 52 week low
👍️0
glenn1919 glenn1919 6 months ago
ACET..............................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783
👍️0
JoseyWales88 JoseyWales88 7 months ago
HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target


HC Wainwright and Co reiterates BUY on ACET with a $10.00 price target

👍️0
Mr. Zen Mr. Zen 7 months ago
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We plan to initiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta CAR T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune program to address additional indications beyond lupus nephritis. We look forward to providing a comprehensive update on our autoimmune program to investors in the near term.”

Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
👍️ 1
glenn1919 glenn1919 7 months ago
ACET....................................https://stockcharts.com/h-sc/ui?s=ACET&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
ACET new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ACET new 52 week
👍️0
Monksdream Monksdream 1 year ago
ACET new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting
👍️0
jondoeuk jondoeuk 1 year ago
https://twitter.com/JacobPlieth/status/1673585690716565504
👍️0
masterofdisaster masterofdisaster 3 years ago
No sell off...guess I bet wrong
👍️0
TheFinalCD TheFinalCD 3 years ago
Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned


👍️0
masterofdisaster masterofdisaster 3 years ago
It was weird....I think the MMs drop this at open to begin the sell off today.
👍️0
TheFinalCD TheFinalCD 3 years ago
whats weird is the rally after the offering


this market is upside down

topsy turvey

👍️0
masterofdisaster masterofdisaster 3 years ago
Bought puts today anticipating an offering and there it is.
👍️0
TheFinalCD TheFinalCD 3 years ago
13.20 low start

ACET
👍️0
crudeoil24 crudeoil24 3 years ago
14.20 in AH. Nice day for the clinical FDA phase I trial results.
👍️0
TheFinalCD TheFinalCD 3 years ago
thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca
👍️0
crudeoil24 crudeoil24 3 years ago
Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.
👍️0
crudeoil24 crudeoil24 3 years ago
Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.
👍️0

Your Recent History

NASDAQ
ACET
Adicet Bio
BIT
F21331
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads